Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Person › Details

David Gilham (Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD))

Gilham, David (Celyad 201609– VP RnD before Univ Manchester MCRC + Bristol Univ)


Organisations Organisation Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD)
  Group Celyad (Group)
  Former/major organisation Manchester Cancer Research Centre (MCRC)
  Group University of Manchester (UoM)
Products Product CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
  Product 2 cancer immunotherapy (immuno-oncology, I-O)

Celyad S.A.. (6/6/16). "Press Release: Celyad Appoints Dr. David Gilham as Vice-President of Research & Development". Mont-Saint-Guibert.

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. David Gilham as Vice-President of Research & Development, effective as from 1st of September 2016.

In order to fulfill his new role at Celyad, Dr. Gilham will resign from the Company’s Immuno-Oncology Scientific Advisory Board in August 2016.

Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.

Dr. Christian Homsy, CEO of Celyad: “We are pleased to welcome David to our executive management team, where he brings over 20 years of expertise in the field of CAR-T cells engineering. Based on his experience in engineering and developing T-cell based immunotherapies for cancer treatment, David will head the implementation of our Research and Development strategy for our programs in immuno-oncology.”

Dr. David Gilham: “I am truly excited to be joining Celyad at such an important time in its history. Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad’s unique portfolio of cell therapy candidates in the clinic.”

David will be based in Mont-Saint-Guibert, Belgium and will report directly to Christian Homsy, Chief Executive Officer.

About Celyad

Celyad – previously Cardio3 BioSciences – is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing clinical stage cell therapies in cardiology and oncology, two healthcare segments with high unmet medical needs.

Record changed: 2018-02-20


Picture [iito] – Putting Information into Context 600x102px

More documents for David Gilham

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

» top